Bio-Techne Corp (NASDAQ: TECH) – Time For Strategy Change?

Bio-Techne Corp (NASDAQ:TECH) currently has a daily average trading volume of 1.12M but it saw 1149194 shares traded in last market. With a market cap of 13.16B USD, the company’s current market price of $83.50 came falling about -0.77 while comparing to the previous closing price of $84.15. In past 52 weeks, the stock remained buoying in the range of price level as high as $89.91 and as low as $51.79.

Taking a look at 20-day trading activity of Bio-Techne Corp (TECH) gives us an average price of $71.79, while its current price level is -7.13% below from 52-week high level whereas it is 61.23% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $70.85 while that of 200 days or SMA-200 reads an average of $70.62. A closer look into the stock’s movement over the week reveals that its volatility is standing at 2.99% during that period while stretching the period over a month that increases to 3.03%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 74.70 which implies that the stock is in overbought territory.

The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Scotiabank which initiated the stock as “Sector Outperform” in its note to investors issued on February 08, 2024, recommending a price target of $80 for it. Stifel downgraded its recommendation for the stock as a “Hold” from “Buy” on February 02, 2024 while assigning a price target of $65. UBS also issued its recommendations for the stock as it initiated the price target for the stock is $80.

Over the week, TECH’s stock price is moving 8.37% up while it is 30.45% when we observe its performance for the past one month. Year-to-date it is 8.22% up and over the past year, the stock is showing an upside performance of 2.98%.

The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of 0.55 beat the consensus estimate of 0.55 for the same. In next quarter, company is expected to be making quarterly sales of $289.41M as analysts are expecting the sales for current fiscal year at $1.16B and seeing the company making $1.25B in sales next year. Moreover, analysts are in estimates of $306.76M for current-quarter revenue.

Currently, Bio-Techne Corp’s total number of outstanding shares is 157.64M. Company’s return on investment (ROI) stands at 8.13% and return on equity (ROE) at 10.40%. It has a price to earnings ratio (P/E ratio) of 66.37 while having a 41.16 of forward P/E ratio. Stock’s beta reads 1.31. Stock has a price to book (P/B) ratio of 6.53 while price to sale or P/S ratio amounts to 11.40. Its return on asset (ROA) is 7.63% on average.